Semax

What is Semax?

Semax is a synthetic heptapeptide with the amino acid sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP). It is an analog of the adrenocorticotropic hormone (ACTH) fragment 4-10, modified with a C-terminal Pro-Gly-Pro tripeptide extension that enhances its metabolic stability and prolongs its biological activity in vivo.[5]

Developed at the Institute of Molecular Genetics of the Russian Academy of Sciences, Semax has been the subject of extensive preclinical investigation since the late 1980s. Unlike full-length ACTH, Semax does not stimulate adrenal cortisol production — it retains the neurotrophic properties of the ACTH(4-10) fragment without the hormonal effects associated with the parent molecule.[10]

Research interest in Semax spans neuroprotection, cognitive research applications, stroke recovery, neurotrophin regulation, and pain modulation. The peptide has been studied using intranasal delivery routes in the majority of published preclinical models, leveraging nose-to-brain transport pathways to achieve central nervous system concentrations.[3]

Semax is classified as a research compound. It has not been approved by the FDA for any therapeutic indication. All information presented here reflects findings from published preclinical and in-vitro studies.

Mechanism of Action

Semax’s neuroprotective and cognitive research effects appear to be mediated through several interrelated molecular pathways:[5][10]

• BDNF/TrkB Signaling: Semax has been studied for effects on brain-derived neurotrophic factor (BDNF) protein levels (up to 1.4-fold) and BDNF mRNA expression (up to 3-fold) in the rat hippocampus. It also enhances TrkB receptor phosphorylation, activating downstream neuroprotective and plasticity-related signaling cascades.[5][10]
• Neurotrophin Gene Regulation: Beyond BDNF, Semax stimulates the expression of multiple neurotrophins including NT-3 and NT-4/5 in rat brain, suggesting a broad neurotrophic mechanism rather than selective BDNF activation alone.[11]
• Inflammatory Gene Suppression: Transcriptomic analyses reveal that Semax suppresses the expression of genes related to inflammatory processes following cerebral ischemia, while simultaneously activating genes related to neurotransmission and synaptic function.[3][6]
• Dopaminergic System Modulation: Semax modulates central dopaminergic activity, with studies demonstrating protective effects against MPTP-induced dopaminergic neuronal damage and augmentation of dopamine release in response to psychostimulants.[15][16]
• Immunomodulation: During cerebral ischemia, Semax has been studied for effects on the amount and mobility of immune cells and enhances the expression of chemokine and immunoglobulin genes, suggesting the peptide actively coordinates the neuroimmune response to brain injury.[9]

Key Research Findings

Neuroprotection & Stroke Research

Cerebral ischemia and stroke recovery represent the most extensively studied neuroprotective applications of Semax. Filippenkov et al. (2020) conducted RNA-Seq transcriptomic profiling following transient middle cerebral artery occlusion (tMCAO) in rats, revealing that Semax administration compensated for ischemia-disrupted mRNA expression patterns — suppressing inflammatory cascades while restoring neurotransmission-related gene networks.[3]

Sudarkina et al. (2021) extended these findings with proteomics data, demonstrating that Semax suppressed inflammatory protein markers including MMP-9, c-Fos, and JNK while activating the neuroprotective transcription factor CREB in stroke-damaged brain tissue.[6]

The immunomodulatory dimensions of Semax’s neuroprotective action were characterized by Medvedeva et al. (2017), who showed that the peptide regulated immune response gene expression during cerebral ischemia, enhancing chemokine signaling and immunoglobulin gene expression in ways that appeared to coordinate the neuroimmune response to brain injury.[9]

Stavchansky et al. (2022) published a comparative analysis of Semax and related glyproline peptides in the context of ischemia-reperfusion injury, confirming multi-target neuroprotective mechanisms involving both inflammatory suppression and neurosignaling pathway activation.[13]

Filippenkov et al. (2024) identified 258 differentially expressed genes in rat frontal cortex following Semax administration, with the predominant effect being decreased immune-related gene expression — further supporting the peptide’s role as a transcriptomic regulator of neuroimmune function.[8]

Beyond ischemia models, Liu et al. (2025) demonstrated that Semax promoted motor functional recovery after spinal cord injury by targeting μ-opioid receptors and regulating deubiquitination through the USP18-FTO pathway, expanding the peptide’s neuroprotective research profile beyond stroke to traumatic CNS injury.[2]

Cognitive Research Applications & BDNF Research

Semax’s cognitive research effects are closely linked to its modulation of the BDNF/TrkB signaling axis. Dolotov et al. (2006) published two seminal studies establishing this connection. In the Journal of Neurochemistry, they demonstrated that Semax specifically binds to rat basal forebrain membranes — a region critical for cholinergic projections to the cortex — and has been studied for effects on BDNF protein levels, providing a mechanistic basis for cognitive research applications.[5]

In a complementary Brain Research publication, Dolotov et al. showed that a single Semax application produced a maximal 1.4-fold increase in BDNF protein with concurrent 1.6-fold enhancement of TrkB tyrosine phosphorylation, and a 3-fold increase in exon III BDNF mRNA in the hippocampus — a structure central to learning and memory formation.[10]

Agapova et al. (2007) extended these findings by demonstrating that Semax stimulates the expression of multiple neurotrophin genes, including BDNF, NT-3, and NT-4/5, in rat brain tissue. This broad neurotrophic activation suggests Semax engages multiple neuroprotective and plasticity pathways beyond BDNF alone.[11]

Radchenko et al. (2025) published recent preclinical data demonstrating that Semax and its heptapeptide derivative has been investigated for effects on cognitive functions and reduced amyloid plaque numbers in APP/PS1 transgenic mouse models of Alzheimer’s disease, suggesting relevance to neurodegenerative disease research.[1]

Eremin et al. (2006) reviewed evidence that Semax can augment central dopamine release and stimulate BDNF synthesis, proposing that these dual mechanisms position the peptide as a potential research tool for attention-deficit and neurodevelopmental conditions.[16]

Behavioral & Pain Research

Semax has demonstrated effects on behavioral and pain-related endpoints in multiple preclinical models. Severyanova et al. (2020) examined the peptide’s analgesic effects following both systemic and central administration, reporting that Semax weakened emotional-affective behavioral responses in pain models through modulation of supraspinal brain structures.[7]

Ivanova et al. (2007) conducted a comparative study of the analgesic potency of the parent ACTH(4-10) fragment versus Semax, establishing that the Pro-Gly-Pro modification retained and in some models enhanced the analgesic activity of the parent sequence.[12]

In the domain of mood and stress research, Inozemtseva et al. (2024) demonstrated that Semax exhibited antidepressant-like effects in a chronic unpredictable stress model. The peptide reversed anhedonia and restored hippocampal BDNF levels in chronically stressed rats, linking its behavioral effects to the BDNF signaling mechanism.[4]

Glazova et al. (2021) showed that Semax administration attenuated behavioral and neurochemical alterations induced by early-life fluvoxamine exposure, including reduced anxiety-like behavior, improved learning, and normalized brain biogenic amine levels — suggesting the peptide can counteract developmental serotonergic disruptions.[14]

Koldobskaya et al. (2004) provided additional evidence of dopaminergic neuroprotection, demonstrating that daily intranasal Semax administration decreased the severity of MPTP-induced behavioral disturbances, with effects attributed to both dopaminergic system modulation and the peptide’s broader neurotrophic activity.[15]

Summary of Research

Semax represents one of the most extensively characterized cognitive research peptides in preclinical neuroscience research. Published literature spanning over three decades documents activity across multiple CNS domains:

• Neuroprotection: Transcriptomic and proteomic evidence of inflammatory gene suppression and neurotransmission restoration following cerebral ischemia, spinal cord injury, and neurotoxin exposure.[3][6]
• BDNF Modulation: Rapid upregulation of BDNF protein, BDNF mRNA, and TrkB receptor phosphorylation in hippocampus and basal forebrain — the primary proposed mechanism for cognitive research applications.[5][10]
• Neurotrophin Activation: Broad neurotrophic gene stimulation including NT-3 and NT-4/5 beyond BDNF alone, supporting multi-pathway neuroprotection.[11]
• Behavioral Effects: Antidepressant-like activity, analgesic effects, and protection against developmental neurochemical disruptions in preclinical models.[4][7]
• Dopaminergic System: Protective effects against MPTP-induced dopaminergic damage and modulation of central dopamine release mechanisms.[15][16]

While preclinical evidence is substantial and spans multiple research institutions, controlled human clinical trial data in Western regulatory frameworks remains limited. Semax has not been approved for therapeutic use by the FDA or EMA. Ongoing research continues to characterize the peptide’s mechanisms and potential translational applications.

Frequently Asked Questions

Citations